SMALL CAP IDEA: Poolbeg Pharma and the oral drug that could unlock cancer immunotherapy's biggest problem
Even accounting for the share's doubling in the year-to-date, the valuation still looks modest relative to where the company is in its development arc.
Daily Mail Money
